205 related articles for article (PubMed ID: 34402431)
1. Mutations of p53 associated with pancreatic cancer and therapeutic implications.
Voutsadakis IA
Ann Hepatobiliary Pancreat Surg; 2021 Aug; 25(3):315-327. PubMed ID: 34402431
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
3. p53 mutations cooperate with oncogenic Kras to promote adenocarcinoma from pancreatic ductal cells.
Bailey JM; Hendley AM; Lafaro KJ; Pruski MA; Jones NC; Alsina J; Younes M; Maitra A; McAllister F; Iacobuzio-Donahue CA; Leach SD
Oncogene; 2016 Aug; 35(32):4282-8. PubMed ID: 26592447
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
5. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics update in pancreatic cancer.
Puri A; Saif MW
JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis by deep sequencing of pancreatic juice from patients with pancreatic ductal adenocarcinoma.
Choi MH; Mejlænder-Andersen E; Manueldas S; El Jellas K; Steine SJ; Tjensvoll K; Sætran HA; Knappskog S; Hoem D; Nordgård O; Hovland R; Molven A
BMC Cancer; 2019 Jan; 19(1):11. PubMed ID: 30611220
[TBL] [Abstract][Full Text] [Related]
8. ARF6 and AMAP1 are major targets of
Hashimoto S; Furukawa S; Hashimoto A; Tsutaho A; Fukao A; Sakamura Y; Parajuli G; Onodera Y; Otsuka Y; Handa H; Oikawa T; Hata S; Nishikawa Y; Mizukami Y; Kodama Y; Murakami M; Fujiwara T; Hirano S; Sabe H
Proc Natl Acad Sci U S A; 2019 Aug; 116(35):17450-17459. PubMed ID: 31399545
[TBL] [Abstract][Full Text] [Related]
9.
Gu M; Gao Y; Chang P
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069772
[TBL] [Abstract][Full Text] [Related]
10. Molecular landscape of pancreatic cancer: implications for current clinical trials.
Heestand GM; Kurzrock R
Oncotarget; 2015 Mar; 6(7):4553-61. PubMed ID: 25714017
[TBL] [Abstract][Full Text] [Related]
11. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
12. Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity.
Turrell FK; Kerr EM; Gao M; Thorpe H; Doherty GJ; Cridge J; Shorthouse D; Speed A; Samarajiwa S; Hall BA; Griffiths M; Martins CP
Genes Dev; 2017 Jul; 31(13):1339-1353. PubMed ID: 28790158
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Pancreatic Cancer.
Grant TJ; Hua K; Singh A
Prog Mol Biol Transl Sci; 2016; 144():241-275. PubMed ID: 27865459
[TBL] [Abstract][Full Text] [Related]
14. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract][Full Text] [Related]
15. Genetic landscape of pancreatic cancer: a narrative review.
Yakar DÖ; Bozkırlı BO; Ceyhan GO
Chin Clin Oncol; 2022 Feb; 11(1):5. PubMed ID: 35255694
[TBL] [Abstract][Full Text] [Related]
16. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
17. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma.
Nakamori S; Yashima K; Murakami Y; Ishikawa O; Ohigashi H; Imaoka S; Yaegashi S; Konishi Y; Sekiya T
Jpn J Cancer Res; 1995 Feb; 86(2):174-81. PubMed ID: 7730141
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
Talar-Wojnarowska R; Malecka-Panas E
Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
[TBL] [Abstract][Full Text] [Related]
19. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
[TBL] [Abstract][Full Text] [Related]
20. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
